血小板与淋巴细胞比值、中性粒细胞与淋巴细胞比值及预后营养指数在局部进展期胃癌新辅助化疗中的临床价值。
Clinical Value of PLR, MLR, and NWR in Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
机构信息
Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
Department of Oncology Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
出版信息
Comput Math Methods Med. 2022 May 26;2022:8005975. doi: 10.1155/2022/8005975. eCollection 2022.
OBJECTIVE
The clinical value of platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-white blood cell ratio (NWR) in predicting the prognosis of patients with locally advanced gastric cancer after neoadjuvant chemotherapy (NACT) was studied.
METHODS
A total of 131 patients with locally advanced gastric cancer treated with neoadjuvant chemotherapy in our hospital from May 2015 to June 2018 were selected as the study subjects, and all were treated with neoadjuvant chemotherapy. The relationship between the values of PLR, MLR, and NWR and the efficacy of neoadjuvant chemotherapy and clinical staging was analyzed; all patients were followed up for 3 years. Patients were divided into death group and survival group according to the survival of patients. The predictive value of PLR, MLR, and NWR values for patients' prognosis was analyzed, and the survival rates of patients with different PLR, MLR, and NWR values were compared.
RESULTS
The effective rate of neoadjuvant chemotherapy in patients with locally advanced gastric cancer was 62.60% (82/131), and the PLR, MLR, and NWR values in the effective group were lower than those in the ineffective group ( < 0.05). The AUC of combined PLR, MLR, and NWR in evaluating the efficacy of neoadjuvant chemotherapy was greater than that of PLR and NWR alone ( < 0.05). The PLR value of patients with stage IIIa, IIIb, and IIIc was greater than that of patients with stage II, the MLR value of patients with stage IIIb and IIIc was greater than that of patients with stage II and IIIa, and the NMR value of patients with stage IIIc was greater than that of patients with stage II, IIIa, and IIIb ( < 0.05). PLR, MLR, and NWR values were positively correlated with clinical stage ( < 0.05). The PLR, MLR, and NWR values in the survival group were lower than those in the death group ( < 0.05). The AUC of combined PLR, MLR, and NWR in predicting the prognosis of patients was greater than that of MLR and NWR alone ( < 0.05). The survival rate of patients with PLR ≥ 162.11 (36.21%) was lower than that of patients with PLR < 162.11 (80.82%), and the survival rate of patients with MLR ≥ 0.31 (42.86%) was lower than that of patients with MLR < 0.31 (74.67%), and the survival rate of patients with NWR ≥ 0.62 (45.00%) was lower than that of patients with NWR < 0.62 (74.65%) ( < 0.05).
CONCLUSIONS
PLR, MLR, and NWR values are correlated with clinical stage, and the combined detection has value in evaluating the clinical efficacy of neoadjuvant chemotherapy and predicting the prognosis of patients with locally advanced gastric cancer.
目的
研究血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）和中性粒细胞与白细胞比值（NWR）在预测局部晚期胃癌患者新辅助化疗（NACT）后预后中的临床价值。
方法
选取 2015 年 5 月至 2018 年 6 月我院收治的局部晚期胃癌患者 131 例作为研究对象，均行新辅助化疗，分析 PLR、MLR 和 NWR 值与新辅助化疗疗效及临床分期的关系；所有患者均随访 3 年，根据患者生存情况将其分为死亡组和生存组，分析 PLR、MLR 和 NWR 值对患者预后的预测价值，并比较不同 PLR、MLR 和 NWR 值患者的生存率。
结果
局部晚期胃癌患者新辅助化疗有效率为 62.60%（82/131），有效组 PLR、MLR、NWR 值均低于无效组（<0.05）；联合检测 PLR、MLR、NWR 评估新辅助化疗疗效的 AUC 大于 PLR 与 NWR 单项检测（<0.05）。Ⅲa、Ⅲb、Ⅲc 期患者的 PLR 值大于Ⅱ期患者，Ⅲb、Ⅲc 期患者的 MLR 值大于Ⅱ期和Ⅲa 期患者，Ⅲc 期患者的 NMR 值大于Ⅱ期、Ⅲa 期和Ⅲb 期患者（<0.05）。PLR、MLR、NWR 值与临床分期呈正相关（<0.05）。生存组 PLR、MLR、NWR 值均低于死亡组（<0.05）。联合检测 PLR、MLR、NWR 预测患者预后的 AUC 大于 MLR 和 NWR 单项检测（<0.05）。PLR≥162.11 的患者生存率（36.21%）低于 PLR<162.11 的患者（80.82%），MLR≥0.31 的患者生存率（42.86%）低于 MLR<0.31 的患者（74.67%），NWR≥0.62 的患者生存率（45.00%）低于 NWR<0.62 的患者（74.65%）（<0.05）。
结论
PLR、MLR、NWR 值与临床分期相关，联合检测对评估局部晚期胃癌患者新辅助化疗的临床疗效及预测患者预后有一定价值。
Zotero 插件